- Home
- DHF vs TIL Comparison
DHF vs TIL Comparison
Compare DHF & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- TIL
- Stock Information
- Founded
- DHF 1998
- TIL 2018
- Country
- DHF United States
- TIL United States
- Employees
- DHF N/A
- TIL N/A
- Industry
- DHF Finance Companies
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- DHF Finance
- TIL Health Care
- Exchange
- DHF Nasdaq
- TIL Nasdaq
- Market Cap
- DHF 185.7M
- TIL 177.1M
- IPO Year
- DHF N/A
- TIL 2021
- Fundamental
- Price
- DHF $2.55
- TIL $14.97
- Analyst Decision
- DHF
- TIL Strong Buy
- Analyst Count
- DHF 0
- TIL 5
- Target Price
- DHF N/A
- TIL $100.67
- AVG Volume (30 Days)
- DHF 451.1K
- TIL 75.3K
- Earning Date
- DHF 01-01-0001
- TIL 11-13-2025
- Dividend Yield
- DHF 7.65%
- TIL N/A
- EPS Growth
- DHF N/A
- TIL N/A
- EPS
- DHF N/A
- TIL N/A
- Revenue
- DHF N/A
- TIL N/A
- Revenue This Year
- DHF N/A
- TIL N/A
- Revenue Next Year
- DHF N/A
- TIL N/A
- P/E Ratio
- DHF N/A
- TIL N/A
- Revenue Growth
- DHF N/A
- TIL N/A
- 52 Week Low
- DHF $2.06
- TIL $10.80
- 52 Week High
- DHF $2.39
- TIL $42.79
- Technical
- Relative Strength Index (RSI)
- DHF 42.17
- TIL 34.46
- Support Level
- DHF $2.56
- TIL $18.10
- Resistance Level
- DHF $2.58
- TIL $20.11
- Average True Range (ATR)
- DHF 0.02
- TIL 1.16
- MACD
- DHF -0.00
- TIL -0.31
- Stochastic Oscillator
- DHF 25.83
- TIL 3.36
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.